DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2011; 136(49): 2560-2561DOI: 10.1055/s-0031-1292831 Kommentar | Commentary Leitlinien © Georg Thieme Verlag KG Stuttgart · New York Wer schützt Ärzte und Patienten vor Leitlinien? Who protects physicians and patients from guidelines? M. Wehling Recommend Article Abstract Buy Article Schlüsselwörter SchlüsselwörterLeitlinien - vorschnelle Änderung - Einzelstudien Keywords Keywordsguidelines - premature adaption - solitary studies Full Text References Literatur 1 European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429 2 European Medicines Agency (EMA). European Medicines Agency recommends restricting use of Multaq. http://www.ifap.de Letzter Zugriff: 9.11.2011 3 Philippin Y. Multaq: vers la fin du remboursement. http://www.liberation.fr Letzter Zugriff: 9.11.2011 4 Sanofi Aventis. Sanofi provides Multaq® Phase IIIb PALLAS Trial update. http://en.sanofi.com Letzter Zugriff: 9.11.2011 5 Serebruany VL.. Aspirin dose and ticagrelor benefit in PLATO: fact or fiction?. Cardiology 2010; 117: 280-283 6 Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555